证券记录 · 已归档季度
EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
18被追踪持有人
n/aΔ持有人
60.09M持有股份
$5.55B报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 14.87M | $1.28B | n/a | n/a |
| Q2 2026 | 163 | -6 | 423.46M | $38.23B | +2 | −9 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | n/a | n/a |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | n/a | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | n/a |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | n/a | 60.09M | $5.55B | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 16.92M | n/a | $1.56B | 0.3% | n/c | 1 | SEC ↗ ×9 |
| 2 | Geode Capital Management ✦ (被动) | 13.24M | n/a | $1.22B | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (被动) | 8.54M | n/a | $788.63M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Fisher Asset Management ✦ | 8.27M | n/a | $764.05M | 0.3% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 7.34M | n/a | $677.60M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 6 | PRIMECAP Management ✦ | 1.81M | n/a | $167.28M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 649.66K | n/a | $60.01M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 624.40K | n/a | $57.68M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 524.21K | n/a | $48.42M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Bridgewater Associates ✦ | 519.81K | n/a | $48.02M | 0.3% | n/c | 1 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 444.16K | n/a | $41.03M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Baillie Gifford ✦ | 352.30K | n/a | $32.54M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 13 | AQR Capital Management ✦ | 309.12K | n/a | $28.55M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 14 | Arrowstreet Capital ✦ | 225.02K | n/a | $20.79M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 152.01K | n/a | $14.04M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 89.65K | n/a | $8.28M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 17 | Marshall Wace ✦ | 74.67K | n/a | $6.90M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 11.86K | n/a | $1.10M | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 4 持有人, 229.24K 股份, $319,498 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 08
Lippis Daniel J.
Officer · 619 股 · $53,017
Sep 11
Lippis Daniel J.
Officer · 619 股 · $54,169
Aug 31
Dahl Andrew M.
Officer · 544 股 · $49,534
Aug 28
Bruls Annette
Officer · 2.64K 股 · $237,907
Aug 26
Markowitz Wayne
Officer · 1.24K 股 · $113,417
Aug 26
Chopra Daveen
Officer · 1.15K 股 · $105,893
Aug 26
Chopra Daveen
Officer · 30.65K 股 · $2.79M
Aug 11
Lippis Daniel J.
Officer · 619 股 · $56,967
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据